胰高糖素样肽-1受体激动剂安全性问题对临床治疗的影响  

The Effect of GLP-1 Receptor Agonist safety on Clinical Therapy

作　　者：李延兵[1] LI Yan-bing(Department of Endocrinology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou Guangdong 510080,China)

机构地区：[1]中山大学附属第一医院内分泌内科,广东广州510080

出　　处：《药品评价》2020年第S01期48-52,共5页Drug Evaluation

摘　　要：胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)已被指南推荐优先用于2型糖尿病合并心血管疾病及高风险的人群。随着其应用范围的扩大,药物相关不良反应和安全性问题也需加以关注。GLP-1 RA最常见不良反应是胃肠道症状,导致患者不能耐受而停药。其次,需对低血糖、免疫源性等问题进行预防和处理。还有用药后是否增加肿瘤和胰腺炎等严重不良结局也需要进行考虑。这些安全性顾虑都会影响治疗策略的选择和患者的接受程度。充分认识GLP-1 RA安全性问题、恰当进行临床应对,可以解除医患双方在应用中的顾虑,提高治疗依从性和持久性,从而获得临床治疗获益。Recently,GLP-1 RA are increasingly recommended by international guidelines in patients with type 2 diabetes mellitus who are diagnosed with CVD or in high risk of CVD.However,safety concerns have raised as its extensive use.Gastrointestinal disorders were the most frequently reported AEs which led to therapy discontinuation.Secondly,hypoglycaemia,immunogenicity and other safety issues should also be prevented and handled properly.Moreover,Physicians should also consider the potential risk of severe adverse events,such as tumour and pancreatitis.All these safety concerns might affect the selection of therapeutic regimens and patient acceptance.Sufficient awareness of the safety profile of GLP-1 RA and appropriate clinical management is helpful to reduce the worries over initiating GLP-1 RA,thereby increasing patient compliance and resulting in clinical benefits.

关 键 词：胰高糖素样肽-1受体激动剂 安全性 胃肠道反应 免疫源性 甲状腺髓样癌 

分 类 号：R587.1[医药卫生—内分泌]